Tricida, Inc., a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCDA
Previous Symbol
CUSIPN/A
Phone415-429-7800
Debt
Debt-to-Equity Ratio0.11
Current Ratio12.68
Quick Ratio2.22
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.20 per share
Price / Book6.02
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees61
Outstanding Shares42,110,000
Market Cap$1.30 billion
OptionableNot Optionable
Tricida (NASDAQ:TCDA) Frequently Asked Questions
What is Tricida's stock symbol?
Tricida trades on the NASDAQ under the ticker symbol "TCDA."
How were Tricida's earnings last quarter?
Tricida Inc (NASDAQ:TCDA) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.19. View Tricida's Earnings History.
When is Tricida's next earnings date?
What price target have analysts set for TCDA?
3 brokerages have issued twelve-month target prices for Tricida's stock. Their predictions range from $32.00 to $50.00. On average, they expect Tricida's stock price to reach $38.6667 in the next twelve months. This suggests a possible upside of 23.5% from the stock's current price. View Analyst Price Targets for Tricida.
What is the consensus analysts' recommendation for Tricida?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tricida.
Has Tricida been receiving favorable news coverage?
Media stories about TCDA stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tricida earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are some of Tricida's key competitors?
Some companies that are related to Tricida include Alkermes (ALKS), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM), United Therapeutics (UTHR), Amarin (AMRN), Loxo Oncology (LOXO), Taro Pharmaceutical Industries (TARO), GW Pharmaceuticals PLC- (GWPH), Agios Pharmaceuticals (AGIO), Horizon Pharma (HZNP), Emergent Biosolutions (EBS), FibroGen (FGEN), Evotec (EVTCY), Ligand Pharmaceuticals (LGND) and Array Biopharma (ARRY).
Who are Tricida's key executives?
Tricida's management team includes the folowing people:
- Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 47)
- Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 53)
- Dr. Wilhelm Stahl, Chief Technology Officer & Sr. VP (Age 58)
- Steffen Pietzke, VP of Fin. & Chief Accounting Officer
- Dr. Jerry M. Buysse, Chief Scientific Officer & Sr. VP (Age 62)
When did Tricida IPO?
(TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.
When does Tricida's lock-up period expire?
Tricida's lock-up period expires on Tuesday, December 25th. Tricida had issued 11,700,000 shares in its IPO on June 28th. The total size of the offering was $222,300,000 based on an initial share price of $19.00. After the end of Tricida's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Who are Tricida's major shareholders?
Tricida's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (2.63%), BlackRock Inc. (2.39%), JPMorgan Chase & Co. (1.63%), JPMorgan Chase & Co. (1.63%), VHCP Management III LLC (1.55%) and Redmile Group LLC (1.18%). Company insiders that own Tricida stock include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Sandra I Coufal and Steffen Pietzke. View Institutional Ownership Trends for Tricida.
Which major investors are selling Tricida stock?
Which major investors are buying Tricida stock?
TCDA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., VHCP Management III LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Opaleye Management Inc., Bank of New York Mellon Corp, TIAA CREF Investment Management LLC and Teachers Advisors LLC. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.
How do I buy shares of Tricida?
Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tricida's stock price today?
One share of TCDA stock can currently be purchased for approximately $31.30.
How big of a company is Tricida?
Tricida has a market capitalization of $1.30 billion. Tricida employs 61 workers across the globe.
What is Tricida's official website?
How can I contact Tricida?
Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]
MarketBeat Community Rating for Tricida (NASDAQ TCDA)
MarketBeat's community ratings are surveys of what our community members think about Tricida and other stocks. Vote "Outperform" if you believe TCDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
